middle.news
Biotron Launches $1.5M Rights Issue to Fund Sedarex Acquisition and Drug Development
11:32am on Tuesday 18th of November, 2025 AEDT
•
Healthcare
Read Story
Biotron Launches $1.5M Rights Issue to Fund Sedarex Acquisition and Drug Development
11:32am on Tuesday 18th of November, 2025 AEDT
Key Points
Non-renounceable rights issue to raise up to $1.5 million
Acquisition of Sedarex Limited approved by shareholders
SedRx general anaesthetic holds global patents with FDA and EMA regulatory support
Funds to support Sedarex development, Biotron’s antiviral programs, and corporate costs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE